Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).

Yachnin J, Gilje B, Thon K, Johansson H, Brandberg Y, Panaretakis T, Ullén A.

Eur J Cancer. 2018 Jul;97:33-40. doi: 10.1016/j.ejca.2018.03.007. Epub 2018 Apr 21.

PMID:
29685343
3.
4.

Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.

Pappot H, von der Maase H, Ullén A, Agerbæk M; NUCOG - Nordic Urothelial Cancer Oncology Group (NUCOG).

Invest New Drugs. 2018 Aug;36(4):615-618. doi: 10.1007/s10637-017-0528-y. Epub 2017 Oct 28.

PMID:
29081023
5.

Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.

Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, Xie H, Ullén A, Harmenberg U, Lidbrink E, Rolny C, Andersson J, Lundqvist A.

Oncoimmunology. 2017 Jun 14;6(8):e1338238. doi: 10.1080/2162402X.2017.1338238. eCollection 2017.

6.

Erratum: Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis.

Holmsten K, Dohn L, Jensen NV, Shah CH, Jäderling F, Pappot H, Ullén A.

Oncol Lett. 2017 Jun;13(6):5035. doi: 10.3892/ol.2017.6082. Epub 2017 Apr 24.

7.

Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts.

Hjälm-Eriksson M, Ullén A, Johansson H, Levitt S, Nilsson S, Kälkner KM.

Acta Oncol. 2017 Jan;56(1):21-26. doi: 10.1080/0284186X.2016.1253864. Epub 2016 Nov 24.

PMID:
27882806
8.

Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.

Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, Ullén A, Zhivotovsky B, Björkholm M, Panaretakis T.

Blood. 2016 Dec 8;128(23):2655-2665. Epub 2016 Oct 14.

9.

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT.

Farnebo J, Wadelius A, Sandström P, Nilsson S, Jacobsson H, Blomqvist L, Ullén A.

Medicine (Baltimore). 2016 Aug;95(31):e4308. doi: 10.1097/MD.0000000000004308.

11.

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis.

Holmsten K, Dohn L, Jensen NV, Shah CH, Jäderling F, Pappot H, Ullén A.

Oncol Lett. 2016 Aug;12(2):1293-1300. Epub 2016 Jun 23. Erratum in: Oncol Lett. 2017 Jun;13(6):5035.

12.

Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells.

Ronquist KG, Sanchez C, Dubois L, Chioureas D, Fonseca P, Larsson A, Ullén A, Yachnin J, Ronquist G, Panaretakis T.

J Extracell Vesicles. 2016 Mar 7;5:29877. doi: 10.3402/jev.v5.29877. eCollection 2016.

13.

Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.

Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A.

Mol Oncol. 2016 May;10(5):719-34. doi: 10.1016/j.molonc.2015.12.013. Epub 2016 Jan 2.

14.

Assessment of electrophile damage in a human brain endothelial cell line utilizing a clickable alkyne analog of 2-chlorohexadecanal.

Nusshold C, Üllen A, Kogelnik N, Bernhart E, Reicher H, Plastira I, Glasnov T, Zangger K, Rechberger G, Kollroser M, Fauler G, Wolinski H, Weksler BB, Romero IA, Kohlwein SD, Couraud PO, Malle E, Sattler W.

Free Radic Biol Med. 2016 Jan;90:59-74. doi: 10.1016/j.freeradbiomed.2015.11.010. Epub 2015 Nov 11.

15.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J.

Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.

PMID:
26553306
16.

A plea for uniform terminology for patients with urothelial carcinoma treated with chemotherapy prior to radical cystectomy: induction versus neoadjuvant chemotherapy.

Liedberg F, Gudjonsson S, Kollberg P, Ullén A.

Eur Urol. 2015 Oct;68(4):742-3. doi: 10.1016/j.eururo.2015.05.037. Epub 2015 Jun 2. No abstract available.

PMID:
26047581
17.

Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.

Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T.

Oncotarget. 2015 Aug 28;6(25):21740-54.

18.

Covalent adduct formation between the plasmalogen-derived modification product 2-chlorohexadecanal and phloretin.

Üllen A, Nusshold C, Glasnov T, Saf R, Cantillo D, Eibinger G, Reicher H, Fauler G, Bernhart E, Hallstrom S, Kogelnik N, Zangger K, Oliver Kappe C, Malle E, Sattler W.

Biochem Pharmacol. 2015 Feb 15;93(4):470-81. doi: 10.1016/j.bcp.2014.12.017. Epub 2015 Jan 6.

19.

Long-term health-related quality of life after curative treatment for prostate cancer: a regional cross-sectional comparison of two standard treatment modalities.

Hjälm-Eriksson M, Lennernäs B, Ullén A, Johansson H, Hugosson J, Nilsson S, Brandberg Y.

Int J Oncol. 2015 Jan;46(1):381-8. doi: 10.3892/ijo.2014.2734. Epub 2014 Oct 29.

PMID:
25355465
20.

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.

Farnebo J, Grybäck P, Harmenberg U, Laurell A, Wersäll P, Blomqvist LK, Ullén A, Sandström P.

BMC Cancer. 2014 Jun 6;14:408. doi: 10.1186/1471-2407-14-408.

21.

Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.

Shah CH, Viktorsson K, Kanter L, Sherif A, Asmundsson J, Rosenblatt R, Lewensohn R, Ullén A.

Urol Oncol. 2014 Nov;32(8):1215-24. doi: 10.1016/j.urolonc.2014.04.015. Epub 2014 May 28.

PMID:
24880461
22.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I.

J Clin Oncol. 2014 Jan 10;32(2):76-82. doi: 10.1200/JCO.2012.48.5268. Epub 2013 Dec 9.

PMID:
24323035
23.

Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo.

Üllen A, Singewald E, Konya V, Fauler G, Reicher H, Nusshold C, Hammer A, Kratky D, Heinemann A, Holzer P, Malle E, Sattler W.

PLoS One. 2013 May 14;8(5):e64034. doi: 10.1371/journal.pone.0064034. Print 2013.

24.

Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.

Shah CH, Viktorsson K, Sherif A, Kanter L, Grybäck P, Lewensohn R, Sandström P, Nilsson S, Ullén A.

Anticancer Drugs. 2013 Jul;24(6):648-52. doi: 10.1097/CAD.0b013e328360c1c3.

PMID:
23542751
25.

25-Hydroxycholesterol regulates cholesterol homeostasis in the murine CATH.a neuronal cell line.

Waltl S, Patankar JV, Fauler G, Nusshold C, Ullen A, Eibinger G, Wintersperger A, Kratky D, Malle E, Sattler W.

Neurosci Lett. 2013 Feb 28;539:16-21. doi: 10.1016/j.neulet.2013.01.014. Epub 2013 Jan 21.

26.

Phloretin ameliorates 2-chlorohexadecanal-mediated brain microvascular endothelial cell dysfunction in vitro.

Ullen A, Fauler G, Bernhart E, Nusshold C, Reicher H, Leis HJ, Malle E, Sattler W.

Free Radic Biol Med. 2012 Nov 1;53(9):1770-81. doi: 10.1016/j.freeradbiomed.2012.08.575. Epub 2012 Aug 25.

27.

Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking.

Konya V, Üllen A, Kampitsch N, Theiler A, Philipose S, Parzmair GP, Marsche G, Peskar BA, Schuligoi R, Sattler W, Heinemann A.

J Allergy Clin Immunol. 2013 Feb;131(2):532-40.e1-2. doi: 10.1016/j.jaci.2012.05.008. Epub 2012 Jun 15.

PMID:
22704539
28.

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.

Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T.

Cell Death Dis. 2012 Jan 26;3:e262. doi: 10.1038/cddis.2012.1.

29.

Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.

Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, Malmström PU; Nordic Urothelial Cancer Group.

Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.

PMID:
22189383
30.

Management of advanced prostate cancer--new drugs.

Ullén A, Shah CH, Kirkali Z.

Acta Oncol. 2011 Jun;50 Suppl 1:137-40. doi: 10.3109/0284186X.2010.529458. No abstract available.

PMID:
21604954
31.

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.

Benedict A, Figlin RA, Sandström P, Harmenberg U, Ullén A, Charbonneau C, Sandin R, Remák E, Hariharan S, Négrier S.

BJU Int. 2011 Sep;108(5):665-72. doi: 10.1111/j.1464-410X.2010.09957.x. Epub 2011 Jan 25.

32.

Mouse brain plasmalogens are targets for hypochlorous acid-mediated modification in vitro and in vivo.

Ullen A, Fauler G, Köfeler H, Waltl S, Nusshold C, Bernhart E, Reicher H, Leis HJ, Wintersperger A, Malle E, Sattler W.

Free Radic Biol Med. 2010 Dec 1;49(11):1655-65. doi: 10.1016/j.freeradbiomed.2010.08.025. Epub 2010 Aug 31. Erratum in: Free Radic Biol Med. 2011 Apr 1;50(7):903.

33.

Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.

Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T, Nilsson S.

Int J Oncol. 2010 Jul;37(1):15-20.

PMID:
20514392
34.

Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro.

Nusshold C, Kollroser M, Köfeler H, Rechberger G, Reicher H, Ullen A, Bernhart E, Waltl S, Kratzer I, Hermetter A, Hackl H, Trajanoski Z, Hrzenjak A, Malle E, Sattler W.

Free Radic Biol Med. 2010 Jun 15;48(12):1588-600. doi: 10.1016/j.freeradbiomed.2010.02.037. Epub 2010 Mar 11.

35.

Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.

Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, Lennernas B, Linder S, Nilsson S.

Scand J Urol Nephrol. 2009;43(2):98-103. doi: 10.1080/00365590802475904.

PMID:
19101859
36.

Chemotherapy-induced bladder cancer.

Nilsson S, Ullén A.

Scand J Urol Nephrol Suppl. 2008 Sep;(218):89-92. doi: 10.1080/03008880802291832. Review. No abstract available.

PMID:
18815922
37.

Current status of prognostic immunohistochemical markers for urothelial bladder cancer.

Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A, Ullén A.

Tumour Biol. 2008;29(5):311-22. doi: 10.1159/000170878. Epub 2008 Nov 5. Review.

PMID:
18984977
38.

Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer.

Kälkner KM, Ullén A, Wersäll P, Cohn-Cedermark G.

Acta Oncol. 2007;46(6):862-3. No abstract available.

PMID:
17653913
39.

High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique: technical and methodological aspects.

Edgren M, Ekelund AM, Albertsson P, Lundberg LM, Ullen A, Levitt S, Nilsson S, Lennernäs B.

Int J Oncol. 2006 Dec;29(6):1517-24.

PMID:
17088991
40.

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.

Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, Nilsson S.

Acta Oncol. 2005;44(6):644-50.

PMID:
16165924
41.

Prostate cancer cell lines lack amplification: overexpression of HER2.

Ullén A, Lennartsson L, Harmenberg U, Lennernäs B, Majumder K, Holmberg AR, Nilsson S, Elmberger GP.

Acta Oncol. 2005;44(5):490-5.

PMID:
16118083
42.

Studies of the interactions between the anticytokeratin 8 monoclonal antibody TS1, its antigen and its anti-idiotypic antibody alphaTS1.

Erlandsson A, Holm P, Ullén A, Stigbrand T, Sundström BE.

J Mol Recognit. 2003 May-Jun;16(3):157-63.

PMID:
12833571
43.

The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody.

Johansson A, Eriksson D, Ullén A, Löfroth PO, Johansson L, Riklund-Ahlström K, Stigbrand T.

Cancer. 2002 Feb 15;94(4 Suppl):1314-9.

44.

Idiotypic-anti-idiotypic complexes and their in vivo metabolism.

Johansson A, Erlandsson A, Eriksson D, Ullén A, Holm P, Sundström BE, Roux KH, Stigbrand T.

Cancer. 2002 Feb 15;94(4 Suppl):1306-13.

45.

A new specific method for measuring S-100B in serum.

Stigbrand T, Nyberg L, Ullén A, Haglid K, Sandström E, Brundell J.

Int J Biol Markers. 2000 Jan-Mar;15(1):33-40.

PMID:
10763138
46.

Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting.

Sandström P, Johansson A, Ullén A, Rathsman S, Riklund-Ahlström K, Stigbrand T.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3073s-3078s.

PMID:
10541346
47.

H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.

Daws MR, Eriksson M, Oberg L, Ullén A, Sentman CL.

Immunology. 1999 Aug;97(4):656-64.

48.

Stability and immunoreactivity of the monoclonal anticytokeratin antibody TS1 after different degrees of iodination.

Johansson A, Sandström P, Ullén A, Erlandsson A, Sundström B, Ahlström KR, Johansson L, Hietala SO, Stigbrand T.

Acta Oncol. 1999;38(3):329-34.

PMID:
10380824
49.

Epitope specificity of the monoclonal anticytokeratin antibody TS1.

Johansson A, Sandström P, Ullén A, Behravan G, Erlandsson A, Levi M, Sundström B, Stigbrand T.

Cancer Res. 1999 Jan 1;59(1):48-51.

50.

Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: a dosimetric evaluation.

Rossi Norrlund R, Ullén A, Sandström P, Holback D, Johansson L, Stigbrand T, Hietala SO, Riklund Ahlström K.

Cancer. 1997 Dec 15;80(12 Suppl):2689-98.

PMID:
9406726

Supplemental Content

Support Center